>>Signaling Pathways>> Metabolism>> Reproductive Biology>>AC-262536

AC-262536

Catalog No.GC46777

AC-262536은 유익한 동화작용 효과가 있는 선택적 비스테로이드성 안드로겐 수용체 조절제(SARM)입니다.

Products are for research use only. Not for human use. We do not sell to patients.

AC-262536 Chemical Structure

Cas No.: 870888-46-3

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$79.00
재고 있음
5mg
US$72.00
재고 있음
10mg
US$126.00
재고 있음
25mg
US$270.00
재고 있음
50mg
US$459.00
재고 있음
100mg
US$801.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AC-262536 is a selective androgen receptor modulator (SARM; Ki = 5.01 nM).1 It is also a partial agonist of the androgen receptor (EC50 = 1.58 nM in a luciferase assay). AC-262536 is selective for the androgen receptor over a panel of 47 additional human nuclear receptors at 10 µM. It inhibits dihydroxytestosterone-induced proliferation of LNCaP prostate cancer cells when used at concentrations of 0.1 and 1 µM. AC-262536 (3, 10, and 30 mg/kg) reduces plasma luteinizing hormone levels and increases levator ani muscle weight, a marker of anabolic activity, in castrated rats. It exhibits smaller increases in prostate gland and seminal vesicle weight, markers of androgenic activity, compared with testosterone in the same model.

1.Piu, F., Gardell, L.R., Son, T., et al.Pharmacological characterization of AC-262536, a novel selective androgen receptor modulatorJ. Steroid Biochem. Mol. Biol.109(1-2)129-137(2008)

리뷰

Review for AC-262536

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AC-262536

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.